{"id":"haart-immunotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune activation syndrome"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Lipodystrophy"},{"rate":null,"effect":"Immune-related adverse events"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HAART uses a combination of antiretroviral drugs to reduce viral load and restore CD4+ T cell counts in HIV patients. Immunotherapy agents (such as checkpoint inhibitors or therapeutic vaccines) work synergistically to boost anti-HIV and anti-tumor immune responses, potentially improving viral control and addressing HIV-associated malignancies or comorbidities.","oneSentence":"HAART (highly active antiretroviral therapy) suppresses HIV replication while immunotherapy enhances the immune system's ability to recognize and eliminate HIV-infected cells and tumors.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:40:10.481Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV infection with immunotherapy enhancement"},{"name":"HIV-associated malignancies"}]},"trialDetails":[{"nctId":"NCT00270205","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-01","conditions":"HIV Infections","enrollment":28},{"nctId":"NCT01428596","phase":"PHASE1","title":"Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects","status":"UNKNOWN","sponsor":"GeneCure Biotechnologies","startDate":"2010-09","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT02378922","phase":"PHASE1","title":"Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma","status":"WITHDRAWN","sponsor":"Fred Hutchinson Cancer Center","startDate":"2016-06-22","conditions":"AIDS-Related Hodgkin Lymphoma, AIDS-Related Non-Hodgkin Lymphoma, HIV Infection","enrollment":""},{"nctId":"NCT00056797","phase":"PHASE2","title":"Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-03","conditions":"HIV Infections","enrollment":92},{"nctId":"NCT01571466","phase":"PHASE1","title":"A Study to Evaluate the Safety of the HIV-1 Vaccine MVA-B in Chronic HIV-1 Infected Patients Successfully Treated With HAART","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2011-09","conditions":"HIV Infection","enrollment":30},{"nctId":"NCT00979706","phase":"PHASE4","title":"Immune-based Therapy Pilot Study for the Treatment of Primary HIV Infection (PHI-IMD).","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2005-03","conditions":"HIV","enrollment":22},{"nctId":"NCT00013663","phase":"PHASE2","title":"Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":92},{"nctId":"NCT01140139","phase":"PHASE1","title":"Dermal HIV-1 Immunization During Anti-retroviral Therapy Followed by Repeated Treatment Interruptions","status":"COMPLETED","sponsor":"Swedish Institute for Infectious Disease Control","startDate":"2006-09","conditions":"HIV-1","enrollment":12},{"nctId":"NCT00287677","phase":"PHASE4","title":"Induction and Expansion of T Cell Repertoire Using Growth Hormone and Vaccination in HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Germans Trias i Pujol Hospital","startDate":"2006-01","conditions":"HIV Infections","enrollment":33},{"nctId":"NCT00381212","phase":"PHASE1, PHASE2","title":"A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent.","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2006-09","conditions":"HIV Seropositivity, Acquired Immunodeficiency Syndrome","enrollment":10},{"nctId":"NCT00052182","phase":"PHASE1","title":"Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-10","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT00329251","phase":"PHASE4","title":"Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIV","status":"COMPLETED","sponsor":"Hospital Clinic of Barcelona","startDate":"2003-04","conditions":"HIV","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":128,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cyclosporine A","GM-CSF","Peg-IFN","Interleukin-2"],"phase":"marketed","status":"active","brandName":"HAART + Immunotherapy","genericName":"HAART + Immunotherapy","companyName":"Juan A. Arnaiz","companyId":"juan-a-arnaiz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HAART (highly active antiretroviral therapy) suppresses HIV replication while immunotherapy enhances the immune system's ability to recognize and eliminate HIV-infected cells and tumors. Used for HIV infection with immunotherapy enhancement, HIV-associated malignancies.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}